ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

In a recent study published in the Annals of Internal Medicine, researchers assess the efficacy of monoclonal antibodies (mAbs) in treating coronavirus disease 2019 (COVID-19) caused by different ...

MSD acquired tulisokibart in 2023 through its buyout of Prometheus Therapeutics.

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025 Enrollment completed ahead of schedule ...

I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...

What happens when the measles virus meets a human cell? The viral machinery unfolds in just the right way to reveal key pieces that let it fuse itself into the host cell membrane. Once the fusion ...

Monoclonal antibody (mAb)-based therapeutics are emerging as one of the fastest-growing categories of drugs being developed today. In fact, according to a recent analysis, 1 the market for mAbs has ...

Failing to maintain the MAB can lead to penalties, which could range from monthly maintenance fees to, in some cases, account closure. (Image: Freepik) The Monthly Average Balance (MAB) is the average ...